Cargando…
Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070
BACKGROUND: Despite intensive research and novel adjuvant therapies, there is currently no cure for metastatic melanoma. The chemokine receptor CXCR4 controls metastasis to sites such as the liver; however, the therapeutic blockade with the existing agents has proven difficult. METHODS: AMD11070, a...
Autores principales: | O'Boyle, G, Swidenbank, I, Marshall, H, Barker, C E, Armstrong, J, White, S A, Fricker, S P, Plummer, R, Wright, M, Lovat, P E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668477/ https://www.ncbi.nlm.nih.gov/pubmed/23538388 http://dx.doi.org/10.1038/bjc.2013.124 |
Ejemplares similares
-
The orally bioavailable allosteric CXCR4 HIV-1 entry inhibitor AMD11070
por: Fricker, Simon, et al.
Publicado: (2012) -
CXCL12–CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy
por: Singh, S, et al.
Publicado: (2010) -
CXCR7-mediated progression of osteosarcoma in the lungs
por: Goguet-Surmenian, E, et al.
Publicado: (2013) -
Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus
por: Boer, J C, et al.
Publicado: (2013) -
CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
por: Bronger, Holger, et al.
Publicado: (2016)